CLARA DAY ON OPERATIONS RESEARCH IN …xie/CLARA/Peter Pauwels CLARA 17112010_AM...SPEEDING UP PROGRESS Under the aegis of the BullukianFoundation CLARA DAY ON OPERATIONS RESEARCH

S P E E D I N G U P P R O G R E S S

Under the aegis of the Bullukian Foundation

CLARA DAY ON OPERATIONS RESEARCH IN

CANCER TREATMENT & OPERATION MANAGEMENT

S P E E D I N G U P P R O G R E S S

Under the aegis of the Bullukian Foundation

November 17, 2010

Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian

Seven Cancer Research Networks within France

• To facilitate and coordinate Cancer research,in particular Translational Research.

• Coordination by French National Cancer Institute (INCa).

Cancer in FranceIncidence 315,000 / yearMortality 150,000 / year

P 2

Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010

CLARA: research network organization

European and international dimension

P 3


CLARA goals

Rapid transferof research to patients

Economic developmentof oncology research

TranslationalCancer Research

P 4


CLARA major partners with international leadership position

CEA-Leti : AtomicEnergy Commission –Electronic and Information Technology LaboratoryCERN: EuropeanOrganization for NuclearResearchCRMN: European Center for High Field NMRELI : EuropeanLymphoma InstituteIARC: International Agency for Research on CancerELuI: European Lung InstitutePARCC-ARA: Support Platform for ClinicalResearch in Oncology in the inter-region Rhône-Alpes AuvergneWSN: World SarcomaNetwork

LYON

GRENOBLECEA-LetiELuI

GENEVA CERN

CRMNELIIARCPARCCWSN

P 5


CLARA major Cancer pathologies with international leadership position

Lymphoma ELI Pr Coiffier – Pr SallesSarcoma WSN Pr BlayLung LCEH Pr Brambilla

Glioblastoma Pr Honnorat – Pr Berger

Hepatocarcinoma Pr Trepo, Pr Zoulim, Pr Merle

1st

order

2nd

order

P 6


CLARA’s whole spectrum of competitive platforms

Metabolomics

Lab benchGenomics - Epigenomics

Experimental cancer modelsBio informatics

Nanotechnologies

Imaging facilities

Pharmacogenomics

Proteomics

Cancer epidemiologyCancer prevention

Clinical researchHadrontherapy

Bio therapiesPatient bed site

€ 50M investment

P 7


European Observatory of Cancer

http://eu-cancer.iarc.fr/

Data about EuropeFrance

P 8


CLARA Strengths and Key Features

Unique integrated research network focused on oncology in Rhône-Alpes-Auvergne

Brings out, evaluates and assists R&D projects involving interdisciplinary experts at the academic, clinical and private companies level

Flexible, reactive and significant funding thanks to the support of INCa, local authorities, and European funds making possible both the CLARA “Proof of concept” programme and CLARA core projects

Neutral and independent interface towards private investors and research organisations

P 9


CLARA auto-analysis 2007-2010

STRONG POINTSSignificant contribution of CLARA researchers to high-impact journals

Five IBiSA national certifications have been granted to CLARA platforms and three major biological resources centres have been certificated

CLARA Portfolio of 25 Proof of concept projects (€32M) based on academic-clinical-industrial cooperation

Initiation of first class projects for enhanced visibility and attractiveness of research

CLARA mobilises diversified funding resources

P 10


INCa-funded projects

INCa 2009 Activity Report

P 11


Synopsis of bibliometric analysis

Quantitative evolution of publications

P 12

100%

110%

120%

130%

140%

2005 2006 2007 2008 2009

Pro

gre

ss

ion

ind

ex

(20

05

as

10

0%

)

year

World

France

CLARA


Synopsis of bibliometric analysis

Cancéropôles contribution to international visibility

P 13


CLARA’s Proof of Concept programme

Growth of CLARA projects portfolio

P 14

0

5

10

15

20

25

30

2005 2006 2007 2008 2009 2010

Num

ber o

f pro

ject

s

Year

Completed with Proof of Concept

Completed

Ongoing


CLARA PoC economical impact

The projects have generated a variety of economic spillovers. 18 start-ups and SMEs have invested €22 M (versus €10M by CLARA), and 11 companies have reached significant “growth milestones”:

5 start-ups have been created: iDD Biotech, EcrinTherapeutics, Fluoptics, Netris Pharma and Synthelis,1 foreign company subsidiary establishment in the region : OncoTherapy Science from Japan,5 companies raised capital (>€40M) : EDAP TMS, EndoControlMedical, ERYtech Pharma, ImmunID Technologies and Nanobiotix,4 companies are listed on the stock exchange or trade sale: EDAP TMS, Genome Express, Innate Pharma (IPO) and OPi.

P 15


CLARA scientific events

P 16

CLARA organised event co-organised with another Cancéropôle


Priorities for 2011-2014

Further mobilise its network on two priorities: identification and assistance to projects of academic –clinical – industrial partnerships in the field of cancerDevelop synergies with key regional partners and abroad in the frame of project detection, evaluation, maturing and fundingReinforce communication on its strategy, projects and results, especially on the Cancéropôle CLARA’s “Proof of Concept” programmeGain further financial support from INCa, regional authorities, French programmes and European funds to support ambitious projects

P 17


Work plan

P 18

Axis I: “Tumour escape, cell plasticity and targeted therapy”

Axis A: “Evaluation, risk perception and cancer prevention”

Technological platforms and

biological resources centres

Proof of concept

Support to Clinical

Research

Axis II: “Infections and Cancer”

Axis III: “Nanotechnology, imaging and cancer”

Axis B: “Environment, nutrition and cancer”

Axis C: “Hadrontherapy and cancer”

Transverse actions

Priority axes

Emerging axes


CLARA Ambition for 2014

Expand the CLARA Proof of Concept programme in oncology to other European regionsA significant move within its projects from pre-clinical studies to clinical trialsAn increased participation of CLARA teams toEuropean programmes and ambitious initiativesAn acceleration of company creations, development and arrival in the regionA broad-spectrum network of experts providing services to oncology research and patientsA clear visibility of CLARA’s research within the nation and elsewhere in Europe

P 19


Support to Clinical Research

P 20

Information

European Lymphoma Institute (ELI)

ClinicalPARCC-ARA

platform

Support to CLARA’s major

cancer pathologies

PHRC cancer

Data management

Training

World Sarcoma Network (WSN)

European Lung Institute (ELuI)

In support of Measure 4, Cancer Plan II to stimulate clinical research


Project of Evaluation, Risk Perception and Cancer Prevention

P 21

•In support of Measure 2, Cancer Plan II to understand through research and reduce inequalities in relation to cancer•With support of the interregional Regional Resources Centre for Information, Prevention and Education about Cancers (Hygée centre, St-Etienne)

Collective / individual decision-makingQuantitative analysisQualitative analysis

Prevention

Therapeutic management

Primary preventionIdentification of risk factorsPatients’ perception of risks

ScreeningEvaluation of screening programmesDeterminants of participation to screening programmesTargeted interventions in non-participative population

Links

Therapeutic management optimisationHomecarePatients education programmes

Axis III

Axis B


Project of Evaluation, Risk Perception and Cancer Prevention

P 22

Prev

entio

nTh

erap

eutic

m

anag

emen

t

Patients involvement

Health inequalities

Education of intermediaries for cancer mass screening in non-privileged areas Reasons for either participating or not to cancer mass screening

Optimum mapping of various organisational methods according to geographical, epidemiological and demographic situations

Develop a multidisciplinary approachStudy the role and consequences of inequalities rather than their description Participate to the development of methods to evaluate interventions to reduce health inequalities

Economic study on adherence to clinical practice in sarcoma Determinants of therapeutic management for patients with broncho-pulmonar cancer Evaluation of therapeutic management of hospital vs. home chemotherapy

Health inequalities for breast and colon cancer screening


Thanks to our partners

P 23

Documents

CLARA DAY ON OPERATIONS RESEARCH IN …xie/CLARA/Peter Pauwels CLARA 17112010_AM...SPEEDING UP PROGRESS Under the aegis of the BullukianFoundation CLARA DAY ON OPERATIONS RESEARCH